These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 25922609)

  • 1. Progression of autosomal dominant kidney disease: measurement of the stage transitions of chronic kidney disease.
    Blanchette CM; Liang C; Lubeck DP; Newsome B; Rossetti S; Gu X; Gutierrez B; Lin ND
    Drugs Context; 2015; 4():212275. PubMed ID: 25922609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Excess healthcare costs in patients with autosomal dominant polycystic kidney disease by renal dysfunction stage.
    Gagnon-Sanschagrin P; Liang Y; Sanon M; Oberdhan D; Guérin A; Cloutier M
    J Med Econ; 2021; 24(1):193-201. PubMed ID: 33464936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAPID-ADPKD (Retrospective epidemiological study of Asia-Pacific patients with rapId Disease progression of Autosomal Dominant Polycystic Kidney Disease): study protocol for a multinational, retrospective cohort study.
    Ryu H; Park HC; Oh YK; Sangadi I; Wong A; Mei C; Ecder T; Wang AY; Kao TW; Huang JW; Rangan GK; Ahn C
    BMJ Open; 2020 Feb; 10(2):e034103. PubMed ID: 32034027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the US.
    Blanchette CM; Craver C; Belk KW; Lubeck DP; Rossetti S; Gutierrez B
    J Med Econ; 2015 Apr; 18(4):303-11. PubMed ID: 25372357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data.
    Knight T; Schaefer C; Krasa H; Oberdhan D; Chapman A; Perrone RD
    Clinicoecon Outcomes Res; 2015; 7():123-32. PubMed ID: 25759590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare Resource Utilization and Costs Associated with Autosomal Dominant Polycystic Kidney Disease.
    Blanchette CM; Iorga ŞR; Altan A; Seare JG; Fan Y; Rossetti S; Gutierrez B
    J Health Econ Outcomes Res; 2014; 2(1):63-74. PubMed ID: 37664083
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
    Clark LA; Whitmire S; Patton S; Clark C; Blanchette CM; Howden R
    J Med Econ; 2017 Jul; 20(7):715-722. PubMed ID: 28332417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiographic Imaging in Autosomal Dominant Polycystic Kidney Disease: A Claims Analysis.
    Sanon Aigbogun M; Stellhorn RA; Pao CS; Seliger SL
    Int J Nephrol Renovasc Dis; 2021; 14():133-142. PubMed ID: 33994802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pain and Health-Related Quality of Life in Autosomal Dominant Polycystic Kidney Disease: Results from a National Patient-Powered Registry.
    Hoover E; Holliday V; Merullo N; Oberdhan D; Perrone RD; Rusconi C; Park M; Phadnis MA; Thewarapperuma N; Dahl NK
    Kidney Med; 2024 May; 6(5):100813. PubMed ID: 38689835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-Reported Outcomes Measures, Polycystic Kidney Disease Burden, and Outcomes in Autosomal Dominant Polycystic Kidney Disease.
    Oberdhan D; Yarlas A; Bjorner JB; Krasa H
    Kidney Med; 2024 Jan; 6(1):100755. PubMed ID: 38192435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality risk in patients with autosomal dominant polycystic kidney disease.
    Mladsi D; Zhou X; Mader G; Sanon M; Wang J; Barnett C; Willey C; Seliger S
    BMC Nephrol; 2024 Feb; 25(1):56. PubMed ID: 38365638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Clinical Manifestation and Management of Autosomal Dominant Polycystic Kidney Disease in China.
    Xue C; Zhou CC; Wu M; Mei CL
    Kidney Dis (Basel); 2016 Oct; 2(3):111-119. PubMed ID: 27921038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and Characterization of Novel Mutations in Chronic Kidney Disease (CKD) and Autosomal Dominant Polycystic Kidney Disease (ADPKD) in Saudi Subjects by Whole-Exome Sequencing.
    Alzahrani OR; Alatwi HE; Alharbi AA; Alessa AH; Al-Amer OM; Alanazi AFR; Shams AM; Alomari E; Naser AY; Alzahrani FA; Hosawi S; Alghamdi SM; Abdali WA; Elfaki I; Hawsawi YM
    Medicina (Kaunas); 2022 Nov; 58(11):. PubMed ID: 36422197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal cyst evolution in childhood: a contemporary observational study.
    Rediger C; Guerra LA; Keays MA; Wayne C; Reddy D; Ksara S; Leonard MP
    J Pediatr Urol; 2019 Apr; 15(2):188.e1-188.e6. PubMed ID: 30808538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
    Coban M; Inci A
    Int Urol Nephrol; 2018 Jul; 50(7):1293-1300. PubMed ID: 29654395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
    Bennett H; McEwan P; Hamilton K; O'Reilly K
    BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial.
    Perico N; Ruggenenti P; Perna A; Caroli A; Trillini M; Sironi S; Pisani A; Riccio E; Imbriaco M; Dugo M; Morana G; Granata A; Figuera M; Gaspari F; Carrara F; Rubis N; Villa A; Gamba S; Prandini S; Cortinovis M; Remuzzi A; Remuzzi G;
    PLoS Med; 2019 Apr; 16(4):e1002777. PubMed ID: 30951521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial.
    Gansevoort RT; Hariri A; Minini P; Ahn C; Chapman AB; Horie S; Knebelmann B; Mrug M; Ong ACM; Pei YPC; Torres VE; Modur V; Antonshchuk I; Perrone RD
    Am J Kidney Dis; 2023 May; 81(5):517-527.e1. PubMed ID: 36535535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.
    Pastor-Soler NM; Li H; Pham J; Rivera D; Ho PY; Mancino V; Saitta B; Hallows KR
    Am J Physiol Renal Physiol; 2022 Jan; 322(1):F27-F41. PubMed ID: 34806449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 Infection in Autosomal Dominant Polycystic Kidney Disease and Chronic Kidney Disease Patients: Progression of Kidney Disease.
    Lai S; Tinti F; Perrotta AM; Salomone L; Cianci R; Izzo P; Izzo S; Izzo L; De Intinis C; Pellicano C; Gigante A
    Biomedicines; 2024 Jun; 12(6):. PubMed ID: 38927508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.